Gram Research analysis shows that the National Institutes of Health launched the Transporter Elucidation Network in 2023 to understand how special gatekeeper proteins control which nutrients, medicines, and chemicals pass from mothers to babies during pregnancy and through breast milk. These transporter proteins act like selective doors in cell membranes, allowing beneficial substances through while blocking harmful ones. By studying these proteins across four research centers using advanced tools like computer modeling and lab-grown tissues, scientists aim to eventually help doctors prescribe safer medicines during pregnancy and protect developing babies from harmful chemical exposure.
The National Institutes of Health launched a major research project in 2023 called the Transporter Elucidation Network to understand how nutrients, medicines, and other substances move from mothers to babies during pregnancy and after birth. Scientists at four research centers are studying special proteins in the placenta, breast milk, and baby brains that act like gatekeepers, deciding what gets through and what stays out. By using advanced tools like computer modeling and lab-grown tissues, researchers hope to figure out how to keep babies healthy and safe from harmful chemicals while making sure they get the nutrients they need to grow.
Key Statistics
The National Institutes of Health launched the Transporter Elucidation Network in 2023 across four research centers to identify and characterize special gatekeeper proteins that control what substances pass from mothers to babies during pregnancy and through breast milk.
According to research reviewed by Gram, the Transporter Elucidation Network uses multiple scientific approaches including proteomics, metabolomics, organoid technology, and machine learning to map how transporter proteins change throughout pregnancy and early infancy.
Research shows that transporter proteins in the placenta, breast tissue, and baby brains function as dual gatekeepers, actively transporting beneficial nutrients like amino acids and vitamins while simultaneously blocking or removing harmful substances from reaching developing babies.
The Transporter Elucidation Network identified that transporter proteins are not static but change dramatically during pregnancy and after birth, meaning substances that can pass through the placenta at one developmental stage may be blocked at another stage.
The Quick Take
- What they studied: How special proteins in the placenta, breast milk, and baby brains control what substances can pass from mother to baby during pregnancy and after birth
- Who participated: This is a research network involving four centers funded by the National Institutes of Health, studying human tissue samples and using computer models rather than testing on people directly
- Key finding: Scientists identified that special gatekeeper proteins called transporters play a critical role in controlling which nutrients, medicines, and chemicals reach developing babies, and they’re creating new tools to study how these proteins work
- What it means for you: This research could eventually help doctors prescribe safer medicines during pregnancy, understand which supplements actually reach babies, and protect developing children from harmful environmental chemicals. However, these are early-stage findings that will take years to translate into practical changes in medical care
The Research Details
The Transporter Elucidation Network is a coordinated research initiative launched by the National Institutes of Health in 2023 across four specialized research centers. Rather than conducting a single study, TEN uses multiple scientific approaches working together. Researchers examine human tissue samples from the placenta (the organ connecting mother and baby), breast tissue, baby brains, and intestines to identify and map special proteins called transporters. These transporters are like selective doors in cell membranes that decide which substances can enter or leave cells.
The network combines several research methods to understand how these transporters work. Experimental approaches involve studying real human tissues and growing miniature tissue models in the lab called organoids. Computational methods use artificial intelligence and computer modeling to predict how transporters function. Researchers also analyze blood samples and use advanced imaging techniques to see where transporters are located and how they change during pregnancy and infancy.
This multidisciplinary approach allows scientists to study the same transporters from multiple angles simultaneously. By combining laboratory experiments with computer predictions and real-world data, the network can develop a complete picture of how substances move between mothers and babies at different stages of development.
Understanding transporter proteins is crucial because they control what reaches developing babies. During pregnancy, the placenta acts as a selective barrier, and after birth, breast milk provides nutrition through special transport mechanisms. Additionally, the blood-brain barrier in babies develops differently than in adults, making babies potentially more vulnerable to certain chemicals. By mapping these transporters and understanding how they work, scientists can predict which medicines are safe during pregnancy, which supplements actually benefit babies, and which environmental chemicals pose risks. This knowledge could transform how doctors prescribe medications to pregnant women and how we protect infants from harmful exposures.
This research initiative represents a major commitment from the National Institutes of Health, indicating high scientific priority and rigorous oversight. The network’s use of multiple complementary research methods (experimental, computational, and translational) strengthens confidence in findings. The involvement of four specialized centers allows for validation across different laboratories. However, this is a descriptive paper about research infrastructure rather than reporting completed findings, so the actual scientific results are still emerging. The work is published in Clinical Pharmacology and Therapeutics, a peer-reviewed journal focused on drug science, which adds credibility. Readers should understand this represents the beginning of a long-term research effort, not final answers about pregnancy and infant safety
What the Results Show
The Transporter Elucidation Network has established a systematic approach to identifying and characterizing transporter proteins across four critical biological barriers: the placenta, lactating breast tissue, the developing brain, and the infant intestine. Researchers have begun mapping which transporter proteins exist in each location and how their expression changes throughout pregnancy and early infancy. The network is using advanced tools including proteomics (identifying all proteins present), metabolomics (tracking nutrient and chemical movement), and organoid technology (growing miniature tissue models) to understand how these transporters function as gatekeepers.
A key finding is that transporter proteins are not static but change dramatically during pregnancy and after birth as the fetus and infant develop. This means that what can pass through the placenta at one stage of pregnancy may be blocked at another stage. Similarly, the blood-brain barrier in newborns functions differently than in older children, potentially allowing some substances to reach the brain that would be blocked later in development. The network is using machine learning and computer modeling to predict how different medicines and chemicals will behave based on their chemical properties and the transporters present in each tissue.
The research has also revealed that transporters serve dual functions: they actively transport beneficial nutrients like amino acids and vitamins into the fetus and newborn, while simultaneously blocking or removing harmful substances. This selective transport is essential for healthy development, but it also means that some medicines that would help mothers may not reach babies effectively, while other substances might accumulate to harmful levels.
Beyond mapping transporters, the network is developing new research tools that will accelerate future studies. These include microphysiological systems (tiny lab models that mimic how tissues work), liquid biopsies (analyzing blood samples for transporter activity), and improved computational models. The research has highlighted that transporters in breast tissue work differently than those in the placenta, suggesting that breast milk provides a different type of selective barrier than the placenta. Additionally, the network identified that environmental chemicals and drugs can affect how transporters function, potentially changing what reaches developing babies over time. The research also suggests that genetic differences between individuals may affect transporter function, which could explain why some babies respond differently to medicines or environmental exposures than others.
This research builds on decades of studies showing that the placenta and blood-brain barrier are selective filters, but it represents a major advancement in understanding the specific molecular mechanisms involved. Previous research identified individual transporter proteins, but the Transporter Elucidation Network is the first coordinated effort to comprehensively map all transporters across multiple critical tissues during pregnancy and infancy. The use of advanced tools like organoids and machine learning represents a significant step forward from older research methods. This work also addresses a major gap in pediatric pharmacology: most medicines are tested in adults, and we have limited understanding of how they reach and affect developing babies. By systematically studying transporters, researchers can now predict medicine behavior in pregnancy and infancy rather than relying on trial and error.
This research initiative is still in early stages, so definitive clinical recommendations cannot yet be made. The studies use human tissue samples and lab models, which may not perfectly replicate how transporters work inside living pregnant women and babies. The research focuses on identifying and characterizing transporters but has not yet completed studies on how to modify transporter function therapeutically. Additionally, the network’s findings will need to be validated through clinical studies before changing medical practice. The research also cannot yet account for all individual differences in how transporters function based on genetics, nutrition, or other factors. Finally, while the network studies human tissues, some findings may still require confirmation through additional research methods before being applied to clinical care
The Bottom Line
Based on this research framework, current recommendations remain unchanged: pregnant women should continue following their doctor’s guidance on medicines and supplements, as this research is still developing. However, this work suggests that future medical practice will become more personalized, with doctors potentially able to predict which medicines will safely reach babies and which should be avoided. For now, the strongest recommendation is that pregnant women should discuss all medicines and supplements with their healthcare provider before use, as doctors can currently assess risks based on existing knowledge. This research will eventually enable more precise recommendations, but that timeline is likely several years away. Confidence level: High that this research direction is scientifically sound, but low confidence in specific clinical applications at this time
Pregnant women and women planning pregnancy should care about this research because it will eventually improve medicine safety during pregnancy. Parents of infants should care because it addresses how breast milk and formula interact with baby development. Healthcare providers should follow this research because it will change how they prescribe medicines during pregnancy and infancy. Pharmaceutical companies should care because it will affect drug development and testing. People concerned about environmental chemical exposure during pregnancy and infancy should care because this research addresses how those chemicals reach developing babies. People who should not change their current behavior based on this article: anyone currently taking prescribed medicines during pregnancy should continue following their doctor’s advice, as this research has not yet produced new clinical guidelines
This is a long-term research initiative that began in 2023. Researchers typically need 5 to 10 years to complete comprehensive studies of this scope. Initial findings about specific transporters may emerge within 2 to 3 years, but clinical applications (changes in how doctors prescribe medicines) will likely take 7 to 10 years or longer. The development of new diagnostic tools based on this research may occur on a similar timeline. Realistic expectations: this research will gradually improve medical knowledge over the next decade, with incremental improvements in pregnancy and infant medicine safety rather than sudden breakthroughs
Frequently Asked Questions
What are transporter proteins and why do they matter during pregnancy?
Transporter proteins are special gatekeepers in cell membranes that control which nutrients, medicines, and chemicals can pass from mother to baby. They actively transport beneficial substances like vitamins while blocking harmful ones, making them critical for healthy fetal development and infant safety.
How will this research change pregnancy medicine in the future?
This research will eventually help doctors predict which medicines safely reach babies and which should be avoided during pregnancy. It may enable personalized medicine recommendations based on how individual transporter proteins function, improving safety for both pregnant women and developing babies.
Does this research mean current pregnancy medicines are unsafe?
No. This research is still in early stages and does not change current medical recommendations. Pregnant women should continue following their doctor’s guidance on all medicines and supplements, as doctors can currently assess risks based on existing knowledge.
How does breast milk relate to these transporter proteins?
Transporter proteins in breast tissue control which nutrients and substances pass into breast milk. The network is studying how these transporters differ from placental transporters, which may explain why breast milk provides different selective protection than the placenta during pregnancy.
When will this research produce practical changes in medical care?
Initial findings about specific transporters may emerge within 2 to 3 years, but clinical applications and changes in how doctors prescribe medicines will likely take 7 to 10 years or longer as research is completed and validated through clinical studies.
Want to Apply This Research?
- Users could track medicines and supplements taken during pregnancy or while breastfeeding, noting the date, substance name, and dosage. As research findings emerge, the app could flag which substances have been studied by the Transporter Elucidation Network and provide updated safety information based on new discoveries about how these substances reach babies
- The app could prompt users to discuss any new medicines or supplements with their healthcare provider before starting, emphasizing that pregnancy and breastfeeding change how substances move through the body. Users could set reminders to review their current medicines with their doctor at each prenatal visit, ensuring that prescriptions remain appropriate as pregnancy progresses and transporter function changes
- Long-term tracking could involve recording which medicines and supplements were used during pregnancy and infancy, then correlating this with health outcomes as the child develops. As the Transporter Elucidation Network publishes findings, the app could update its database to show which substances have been studied and what new safety information is available. This creates a longitudinal record that users can share with healthcare providers to improve personalized medicine recommendations
This article describes ongoing research and does not represent established clinical guidelines. Pregnant women and women planning pregnancy should continue following their healthcare provider’s recommendations regarding all medicines and supplements. Do not change any current medications or supplements based on this article without consulting your doctor. The Transporter Elucidation Network is still in early research stages, and clinical applications of these findings may take many years to develop. This information is for educational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.